Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.

[2][4][5] Latanoprostene bunod is indicated for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.

[2] The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension.

[4] In each trial, participants were randomly assigned to receive either latanoprostene bunod or an approved drug timolol (ophthalmic solution) every day for three months.

[4] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed.